Q1 2018 Earnings Forecast for Ra Pharmctl Inc (RARX) Issued By Jefferies Group
Ra Pharmctl Inc (NASDAQ:RARX) – Jefferies Group issued their Q1 2018 earnings estimates for shares of Ra Pharmctl in a report released on Thursday. Jefferies Group analyst E. Yang expects that the company will post earnings per share of ($0.77) for the quarter. Jefferies Group has a “Buy” rating and a $25.00 price target on the stock. Jefferies Group also issued estimates for Ra Pharmctl’s Q2 2018 earnings at ($0.91) EPS, Q3 2018 earnings at ($0.93) EPS and Q4 2018 earnings at ($1.14) EPS.
A number of other research analysts have also issued reports on RARX. Zacks Investment Research lowered shares of Ra Pharmctl from a “hold” rating to a “sell” rating in a report on Tuesday, August 22nd. Royal Bank Of Canada began coverage on shares of Ra Pharmctl in a report on Thursday, September 14th. They issued an “outperform” rating and a $21.00 price objective for the company. Finally, Credit Suisse Group raised their price target on shares of Ra Pharmctl from $19.00 to $23.00 and gave the stock an “outperform” rating in a report on Friday, November 10th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Ra Pharmctl presently has a consensus rating of “Buy” and an average target price of $24.67.
Shares of Ra Pharmctl (NASDAQ:RARX) traded down $0.10 during midday trading on Monday, reaching $14.01. 76,600 shares of the company were exchanged, compared to its average volume of 118,566. Ra Pharmctl has a 1-year low of $11.20 and a 1-year high of $27.84.
Ra Pharmctl (NASDAQ:RARX) last issued its quarterly earnings data on Thursday, November 9th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.06).
Several large investors have recently added to or reduced their stakes in RARX. American International Group Inc. bought a new stake in shares of Ra Pharmctl in the 1st quarter valued at $102,000. TIAA CREF Investment Management LLC increased its stake in shares of Ra Pharmctl by 97.0% in the 1st quarter. TIAA CREF Investment Management LLC now owns 7,837 shares of the company’s stock valued at $167,000 after acquiring an additional 3,859 shares in the last quarter. Alliancebernstein L.P. bought a new stake in shares of Ra Pharmctl in the 2nd quarter valued at $195,000. Wells Fargo & Company MN increased its stake in shares of Ra Pharmctl by 151.8% in the 1st quarter. Wells Fargo & Company MN now owns 9,455 shares of the company’s stock valued at $202,000 after acquiring an additional 5,700 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its stake in shares of Ra Pharmctl by 30.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 10,860 shares of the company’s stock valued at $204,000 after acquiring an additional 2,543 shares in the last quarter. Institutional investors own 66.74% of the company’s stock.
About Ra Pharmctl
Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.
Receive News & Stock Ratings for Ra Pharmctl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmctl Inc and related stocks with our FREE daily email newsletter.